|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alanazi IO and Khan Z: Understanding EGFR
signaling in breast cancer and breast cancer stem cells:
Overexpression and therapeutic implications. Asian Pac J Cancer
Prev. 17:445–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang Y, Wang Y, Kiani MF and Wang B:
Classification, treatment strategy, and associated drug resistance
in breast cancer. Clin Breast Cancer. 16:335–343. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elstrodt F, Hollestelle A, Nagel JH, Gorin
M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP and
Schutte M: BRCA1 mutation analysis of 41 human breast cancer cell
lines reveals three new deleterious mutants. Cancer Res. 66:41–45.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharieh EA, Awidi AS, Ahram M and Zihlif
MA: Alteration of gene expression in MDA-MB-453 breast cancer cell
line in response to continuous exposure to Trastuzumab. Gene.
575:415–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hámori L, Kudlik G, Szebényi K, Kucsma N,
Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, et al:
Establishment and characterization of a brca1−/−,
p53−/− mouse mammary tumor cell line. Int J Mol Sci.
21:11852020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han Y, Nakayama J, Hayashi Y, Jeong S,
Futakuchi M, Ito E, Watanabe S and Semba K: Establishment and
characterization of highly osteolytic luminal breast cancer cell
lines by intracaudal arterial injection. Genes Cells. 25:111–123.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai X, Cheng H, Bai Z and Li J: Breast
cancer cell line classification and its relevance with breast tumor
subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li ZH, Hu PH, Tu JH and Yu NS: Luminal B
breast cancer: Patterns of recurrence and clinical outcome.
Oncotarget. 7:65024–65033. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chun KH, Park JH and Fan S: Predicting and
overcoming chemotherapeutic resistance in breast cancer. Adv Exp
Med Biol. 1026:59–104. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shiga K, Hara M, Nagasaki T, Sato T,
Takahashi H and Takeyama H: Cancer-associated fibroblasts: Their
characteristics and their roles in tumor growth. Cancers (Basel).
7:2443–2458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barak V, Goike H, Panaretakis KW and
Einarsson R: Clinical utility of cytokeratins as tumor markers.
Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu-Monette ZY, Zhang M, Li J and Young KH:
PD-1/PD-L1 blockade: Have we found the key to unleash the antitumor
immune response? Front Immunol. 8:15972017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia L, Zhang Q and Zhang R: PD-1/PD-L1
pathway blockade works as an effective and practical therapy for
cancer immunotherapy. Cancer Biol Med. 15:116–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Narayan P, Wahby S, Gao JJ,
Amiri-Kordestani L, Ibrahim A, Bloomquist E, Tang S, Xu Y, Liu J,
Fu W, et al: FDA approval summary: Atezolizumab plus paclitaxel
protein-bound for the treatment of patients with advanced or
metastatic TNBC whose tumors express PD-L1. Clin Cancer Res.
26:2284–2289. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Capp JP: Cancer stem cells: From
historical roots to a new perspective. J Oncol. 2019:51892322019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Najafi M, Farhood B and Mortezaee K:
Cancer stem cells (CSCs) in cancer progression and therapy. J Cell
Physiol. 234:8381–8395. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lathia JD and Liu H: Overview of cancer
stem cells and stemness for community oncologists. Target Oncol.
12:387–399. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sheridan C, Kishimoto H, Fuchs RK,
Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and
Nakshatri H: CD44+/CD24− breast cancer cells
exhibit enhanced invasive properties: An early step necessary for
metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jonkman JE, Cathcart JA, Xu F, Bartolini
ME, Amon JE, Stevens KM and Colarusso P: An introduction to the
wound healing assay using live-cell microscopy. Cell Adh Migr.
8:440–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meirson T and Gil-Henn H: Targeting
invadopodia for blocking breast cancer metastasis. Drug Resist
Updat. 39:1–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu W, Prasadam I, Yu M, Zhang F, Ling P,
Xiao Y and Yu C: Gamma tocotrienol targets tyrosine phosphatase
SHP2 in mammospheres resulting in cell death through RAS/ERK
pathway. BMC Cancer. 15:6092015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dontu G, Al-Hajj M, Abdallah WM, Clarke MF
and Wicha MS: Stem cells in normal breast development and breast
cancer. Cell Prolif. 36 (Suppl 1):S59–S72. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bailey PC, Lee RM, Vitolo MI, Pratt SJP,
Ory E, Chakrabarti K, Lee CJ, Thompson KN and Martin SS:
Single-cell tracking of breast cancer cells enables prediction of
sphere formation from early cell divisions. iScience. 8:29–39.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bruner HC and Derksen PWB: Loss of
E-cadherin-dependent cell-cell adhesion and the development and
progression of cancer. Cold Spring Harb Perspect Biol.
10:a0293302018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ziegler E, Hansen MT, Haase M, Emons G and
Gründker C: Generation of MCF-7 cells with aggressive metastatic
potential in vitro and in vivo. Breast Cancer Res Treat.
148:269–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang H: Matrix metalloproteinase-9
(MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent
advances. Sensors (Basel). 18:32492018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li H, Qiu Z, Li F and Wang C: The
relationship between MMP-2 and MMP-9 expression levels with breast
cancer incidence and prognosis. Oncol Lett. 14:5865–5870.
2017.PubMed/NCBI
|
|
37
|
Pivetta E, Scapolan M, Pecolo M,
Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C,
Colombatti A and Spessotto P: MMP-13 stimulates osteoclast
differentiation and activation in tumour breast bone metastases.
Breast Cancer Res. 13:R1052011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weiswald LB, Bellet D and Dangles-Marie V:
Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rexer BN, Chanthaphaychith S, Dahlman KB
and Arteaga CL: Direct inhibition of PI3K in combination with dual
HER2 inhibitors is required for optimal antitumor activity in HER2+
breast cancer cells. Breast Cancer Res. 16:R92014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Riaz M, van Jaarsveld MT, Hollestelle A,
Prager-van der Smissen WJ, Heine AA, Boersma AW, Liu J, Helmijr J,
Ozturk B, Smid M, et al: miRNA expression profiling of 51 human
breast cancer cell lines reveals subtype and driver
mutation-specific miRNAs. Breast Cancer Res. 15:R332013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hollestelle A, Nagel JH, Smid M, Lam S,
Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal
MJ, et al: Distinct gene mutation profiles among luminal-type and
basal-type breast cancer cell lines. Breast Cancer Res Treat.
121:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen CC, Feng W, Lim PX, Kass EM and Jasin
M: Homology-directed repair and the role of BRCA1, BRCA2, and
related proteins in genome integrity and cancer. Ann Rev Cancer
Biol. 2:313–336. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lord CJ and Ashworth A: Mechanisms of
resistance to therapies targeting BRCA-mutant cancers. Nat Med.
19:1381–1388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moran A, O'hara C, Khan S, Shack L,
Woodward E, Maher ER, Lalloo F and Evans DG: Risk of cancer other
than breast or ovarian in individuals with BRCA1 and BRCA2
mutations. Fam Cancer. 11:235–242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ledermann JA, Drew Y and Kristeleit RS:
Homologous recombination deficiency and ovarian cancer. Eur J
Cancer. 60:49–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gallagher DJ, Gaudet MM, Pal P, Kirchhoff
T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, et
al: Germline BRCA mutations denote a clinicopathologic subset of
prostate cancer. Clin Cancer Res. 16:2115–2121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Iqbal J, Ragone A, Lubinski J, Lynch HT,
Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL,
et al: The incidence of pancreatic cancer in BRCA1 and BRCA2
mutation carriers. Br J Cancer. 107:2005–2009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Corcoran RB, Dias-Santagata D, Bergethon
K, Iafrate AJ, Settleman J and Engelman JA: BRAF gene amplification
can promote acquired resistance to MEK inhibitors in cancer cells
harboring the BRAF V600E mutation. Sci Signal. 3:ra842010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kolinjivadi AM, Sannino V, de Antoni A,
Técher H, Baldi G and Costanzo V: Moonlighting at replication
forks-a new life for homologous recombination proteins BRCA1, BRCA2
and RAD51. FEBS Lett. 591:1083–1100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Holloman WK: Unraveling the mechanism of
BRCA2 in homologous recombination. Nat Struct Mol Biol. 18:748–754.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shirole NH, Pal D, Kastenhuber ER, Senturk
S, Boroda J, Pisterzi P, Miller M, Munoz G, Anderluh M, Ladanyi M,
et al: TP53 exon-6 truncating mutations produce separation of
function isoforms with pro-tumorigenic functions. Elife.
5:e179292016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shirole NH, Pal D, Kastenhuber ER, Senturk
S, Boroda J, Pisterzi P, Miller M, Munoz G, Anderluh M, Ladanyi M,
et al: TP53 exon-6 truncating mutations produce separation of
function isoforms with pro-tumorigenic functions. Elife.
6:e255322017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huovinen M, Loikkanen J, Myllynen P and
Vähäkangas KH: Characterization of human breast cancer cell lines
for the studies on p53 in chemical carcinogenesis. Toxicol In
Vitro. 25:1007–1017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hui L, Zheng Y, Yan Y, Bargonetti J and
Foster D: Mutant p53 in MDA-MB-231 breast cancer cells is
stabilized by elevated phospholipase D activity and contributes to
survival signals generated by phospholipase D. Oncogene.
25:7305–7310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lu X, Errington J, Curtin NJ, Lunec J and
Newell DR: The impact of p53 status on cellular sensitivity to
antifolate drugs. Clin Cancer Res. 7:2114–2123. 2001.PubMed/NCBI
|
